Steroids vs. NSAIDs in Treating Acute Gout

By Jack Cush, MD | 25 July 2018

Gout, the ancient disease of kings is usually treated with the ancient (and costly) drug colchicine, often without consideration of nonsteroidal antiinflammatory drugs (NSAID) or corticosteroids. A recent metanalysis compared the NSAIDS and steroids and showed that both were equipotent in managing the pain of acute gout, but corticosteroids appear had a more favorable safety profile.

The metanalysis revieweed 6 eligible trials, with a total of 817 gout patients treated with either NSAIDs or corticosteroids and had a followup was 15 days (range 4-30).

By day 7, the pain score was low and not significantly different between the two (SMD -0.09; 95% CI -0.26 to 0.08)

There was no difference in the time to disease resolution, or number of supplementary analgesics used.

However, there was a lower risk of indigestion (RR 0.50, 95% CI 0.27-0.92), nausea (RR 0.25, 95% CI 0.11-0.54), and vomiting (RR 0.11, 95% CI 0.02-0.56) with corticosteroid therapy.

Corticosteroids may be preferred over NSAIDs in managing acute gout as they have less GI adverse events in RCTs.

Disclosures:

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may Login/Register to comment.

More Like This

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

By Olga Petryna, MD | 25 Nov 2019

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

By Olga Petryna, MD | 20 Nov 2019

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

By Jack Cush, MD | 08 Nov 2019

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

[...]

Novel Inhibition of MSU Crystal Inflammation

By Jack Cush, MD | 29 Oct 2019

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β).

[...]

Patients Prefer Nurse Led Care for their Gout

By Jack Cush, MD | 24 Oct 2019

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.

[...]

You are here